Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
复制标题
DOI：
10.1016/j.urolonc.2017.05.013
复制
发表时间：
2017-09-01
影响因子：
2.7
通讯作者：
Harmenberg, Ulrika
中科院分区：
文献类型：
--
作者：
Lindskog, Magnus;Wahlgren, Thomas;Harmenberg, Ulrika
背景：这项回顾性研究调查了瑞典转移性肾细胞癌(MRCC)患者在靶向治疗(TT)之前(2002-2005)、早期(2006-2008)和晚期(2009-2012)的总生存率(OS)及其影响因素。采用Kaplan-Meier方法估计中位OS。采用COX比例风险回归进行多因素分析。对同步转移患者(ML)和老年患者(年龄=75岁)进行亚组分析。结果：共有4,217例肾细胞癌患者，包括1,533例ML患者和1,275名老年患者。2002年至2005年、2006年至2008年和2009年至2012年确诊的肾细胞癌患者的中位OS分别为10.0、13.0和18.0个月。同样，M1和老年人群的中位数OS有所改善。老年患者服用TT处方的可能性较小(>；=75vs.
Background: This retrospective study investigated overall survival (OS) and factors influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the pre- (2002-2005), early (2006-2008), and late (2009-2012) targeted therapy (TT) era.Methods: Three national Swedish registries identified patients with mRCC. Median OS was estimated using the Kaplan-Meier method. Multivariate analysis was performed using Cox proportional hazards regression. Subgroup analysis was conducted for patients with synchronous metastases (Ml) and the elderly (aged >= 75 y).Results: A total of 4,217 patients with mRCC were identified, including 1,533 patients with Ml and 1,275 elderly patients. For patients with mRCC diagnosed in 2002 to 2005, 2006 to 2008, and 2009 to 2012, median OS was 10.0, 13.0, and 18.0 months. Similarly, median OS improved in the M1 and elderly populations. Elderly patients were less likely to be prescribed TT (>= 75 vs.